How to care for caregivers? NCCN debuts essential guide for supporting loved ones with cancer
Book Announcement
Updates every hour. Last Updated: 27-Oct-2026 22:16 ET (28-Oct-2026 02:16 GMT/UTC)
PLOS is delighted to announce a new collaboration between United Nations University Institute for Water, Environment and Health (UNU-INWEH) and PLOS Water: a collection of papers focusing on policy-relevant, science-based solutions.
Researchers at QST have demonstrated for the first time that patients with progressive supranuclear palsy (PSP) whose brain tau protein accumulates more rapidly also experience faster clinical decline. Using a highly sensitive PET imaging technology developed by QST, the team tracked changes in tau accumulation over one year. The findings suggest that slowing tau buildup could slow disease progression and provide a valuable biomarker for future therapeutic trials.
Drug-resistant epilepsy types, such as mesial temporal lobe epilepsy (MTLE), are surgically managed through anterior temporal lobectomy (ATL). However, a significant proportion of patients with MTLE do not qualify for ATL owing to the risk of severe side effects, warranting the need for alternatives. Now, Mexican researchers have examined the therapeutic efficacy of non-invasive linear accelerator (LINAC)-based radiosurgery in MTLE. LINAC-based radiosurgery effectively decreased epilepsy and aura frequency but was associated with several side effects.
In acute pancreatitis, mild obesity might more than double the odds of vital organ failure, according to an international study analyzing data from over 2200 patients by researchers at Semmelweis University. The study, published in the journal Pancreatology, found that patients with obesity may have more than three times the odds of developing severe acute pancreatitis compared with patients of normal weight. Experts therefore emphasize that even a gradual or smaller weight loss might reduce the odds of severe complications.
The intestine engages in communication with various distant organs through neural, immune, and endocrine pathways. This systemic interconnection mechanism is referred to as the gut-organ axis, in which gut microbiota play a central role. The therapeutic landscape is rapidly evolving, with next-generation probiotics, postbiotics, and engineered strains now enabling precise, targeted remodeling of the gut ecosystem to restore host homeostasis and treat multi-organ diseases. This review articulates how the gut microbiota integrates environmental cues into a multi-organ regulatory network, underscoring its potential as a therapeutic target for systemic diseases.